Finerenone Ameliorates High Glucose-Induced Podocytes Epithelial-Mesenchymal Transition Through the Regulation of Krüppel-Like Factor 5 in Diabetic Nephropathy

Authors: Shu J, Chen D, Chen W, Zhang X, Wang S, Chong N, Sun Z, Wang Q, Sun J, Xu Y

Source: Diabetes, Metabolic Syndrome and Obesity, Vol Volume 18, Pp 637-651 (2025)

Subject Terms: finerenone dn emt klf5, Specialties of internal medicine, RC581-951

File Description: electronic resource

Relation: https://www.dovepress.com/finerenone-ameliorates-high-glucose-induced-podocytes-epithelial-mesen-peer-reviewed-fulltext-article-DMSO; https://doaj.org/toc/1178-7007

Access URL: https://doaj.org/article/d848086304a94d21899e7cedafe2aa0f

Finerenone in the management of diabetes kidney disease

Authors: Parijat De, May T Khine, Andrew Frankel, Gabrielle Goldet, Debasish Banerjee, Rosa M Montero, Tahseen A Chowdhury, Damien Fogarty, Janaka Karalliedde, Ritwika Mallik, Dipesh C Patel, Mona Wahba, Peter Winocour, Sagen Zac-Varghese, Stephen Bain, Adnan Sharif, Srikanth Bellary, Indranil Dasgupta

Source: BMC Nephrology, Vol 26, Iss 1, Pp 1-7 (2025)

Subject Terms: Diabetes, Hypertension, Albuminuria, Diabetic kidney disease, Finerenone, ACE inhibitors, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2369

Access URL: https://doaj.org/article/95c1ec77939d4f6589458d7db7d84231

2024 update in heart failure

Authors: Alberto Beghini, Antonio Maria Sammartino, Zoltán Papp, Stephan vonHaehling, Jan Biegus, Piotr Ponikowski, Marianna Adamo, Luigi Falco, Carlo Mario Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra, Daniela Tomasoni

Source: ESC Heart Failure, Vol 12, Iss 1, Pp 8-42 (2025)

Subject Terms: comorbidities, finerenone, heart failure, prevention, prognosis, SGLT2 inhibitors, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/2055-5822

Access URL: https://doaj.org/article/4fb146934c2544e89339c9379c54ce1d

Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes

Authors: Gerasimos Filippatos, Stefan D. Anker, George L. Bakris, Peter Rossing, Luis M. Ruilope, Andrew J.S. Coats, Stephan vonHaehling, Piotr Ponikowski, Giuseppe M.C. Rosano, Meike Brinker, Alfredo E. Farjat, Luke Roberts, Bertram Pitt, the FIDELIO‐DKD and FIGARO‐DKD investigators

Source: ESC Heart Failure, Vol 12, Iss 1, Pp 185-188 (2025)

Subject Terms: Cardiorenal outcomes, Chronic kidney disease, Finerenone, Hospitalization for heart failure, Left ventricular hypertrophy, Type 2 diabetes, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/2055-5822

Access URL: https://doaj.org/article/1910be4cba174c97aaef8e7f1fbcbb31

A new era of cardiac nephroprotection in patients with type 2 diabetes mellitus: the role of Finerenone

Authors: I. S. Khalimov, E. A. Polyakova, Yu. A. Shutova

Source: Сахарный диабет, Vol 27, Iss 6, Pp 620-628 (2025)

Subject Terms: diabetes mellitus, сhronic kidney disease, egfr slope, finerenone, Nutritional diseases. Deficiency diseases, RC620-627

File Description: electronic resource

Relation: https://www.dia-endojournals.ru/jour/article/view/13222; https://doaj.org/toc/2072-0351; https://doaj.org/toc/2072-0378

Access URL: https://doaj.org/article/3c9a80593c8a493faf3ac7e1e49033ce

Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes

Authors: Duc Tin Tran, Emily S. H. Yeung, Lisa Y. Q. Hong, Harmandeep Kaur, Suzanne L. Advani, Youan Liu, Madiha Zahra Syeda, Sri Nagarjun Batchu, Andrew Advani

Source: Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-15 (2024)

Subject Terms: CCN2, CTGF, Diabetic nephropathy, Finerenone, Gastric inhibitory polypeptide, GLP-1, Nutritional diseases. Deficiency diseases, RC620-627

File Description: electronic resource

Relation: https://doaj.org/toc/1758-5996

Access URL: https://doaj.org/article/d83babb7dab34bdbb3c4ab7989772102

Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives

Authors: Kosuke Sawami, Atsushi Tanaka, Koichi Node

Source: Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-11 (2024)

Subject Terms: Glucagon-like peptide-1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Finerenone, Combination therapy, Cardiovascular and kidney outcomes, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/1475-2840

Access URL: https://doaj.org/article/35107f0646fc46afa0af76b5cc1e3b4a

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons

Authors: Yuan Gao, Xin Liu, Yunyi Gao, Meili Duan, Bing Hou, Yu Chen

Source: Gut and Liver, Vol 18, Iss 6, Pp 934-948 (2024)

Subject Terms: renin-angiotensin system, liver cirrhosis, ascites, finerenone, sodium-glucose transporter 2 inhibitors, Diseases of the digestive system. Gastroenterology, RC799-869

File Description: electronic resource

Relation: http://gutnliver.org/journal/view.html?doi=10.5009/gnl240038; https://doaj.org/toc/1976-2283

Access URL: https://doaj.org/article/f9749709438d40e38bf82d11cd6f6dbc

Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension

Authors: O. B. Kuzmin, N. V. Buchneva, V. V. Belyanin, V. V. Zhezha, M. V. Stolbova

Source: Рациональная фармакотерапия в кардиологии, Vol 20, Iss 4, Pp 451-459 (2024)

Subject Terms: resistant arterial hypertension, kidney, epithelial sodium channels, rho gtp-ase rac1, aldosterone synthase inhibitors, mineralcorticoid receptor antagonists, baxdrostat, finerenone, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://www.rpcardio.online/jour/article/view/3064; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/be496d7d8bf642838f6ed14e7feca20d

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials

Authors: Jingyi Guo, Maoying Wei, Wenhua Zhang, Yijia Jiang, Aijing Li, Churan Wang, Dan Yin, Anning Sun, Yanbing Gong

Source: Frontiers in Pharmacology, Vol 16 (2025)

Subject Terms: SGLT-2 inhibitors, GLP-1 receptor agonists, Finerenone, type 2 diabetes mellitus, chronic kidney disease, network meta-analysis, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fphar.2025.1517272/full; https://doaj.org/toc/1663-9812

Access URL: https://doaj.org/article/9896092a54674fb6977371b54de33271

Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms

Authors: Jing Wang, Haojie Xue, Jinyu He, Li Deng, Julong Tian, Yang Jiang, Jian Feng

Source: Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-9 (2024)

Subject Terms: Finerenone, Diabetic cardiomyopathy, Programmed cell death, Oxidative stress, Intestinal microbiota, Nutritional diseases. Deficiency diseases, RC620-627

File Description: electronic resource

Relation: https://doaj.org/toc/1758-5996

Access URL: https://doaj.org/article/7bca7d2f0bac4ed891dd5b8a46fdda7b

A Trial of Finerenone in a Patient with Primary Aldosteronism

Authors: Sandra Karanović Štambuk

Source: Kidney & Blood Pressure Research, Vol 49, Iss 1, Pp 839-842 (2024)

Subject Terms: arterial hypertension, finerenone, mineralocorticoid receptor antagonists, primary aldosteronism, Dermatology, RL1-803, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://beta.karger.com/Article/FullText/541441; https://doaj.org/toc/1423-0143

Access URL: https://doaj.org/article/4f09727ec6de43649b01a3c2a1d9ab7a

Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: A case report

Authors: Cai‐Guo Yu, Bin Cao, Hao‐Lin Gong, Jing Ke, Shao‐Zhong Xian, Nan‐Nan Wu, Dong Zhao

Source: The Journal of Clinical Hypertension, Vol 26, Iss 9, Pp 1116-1120 (2024)

Subject Terms: antihypertensive therapy, finerenone, primary aldosteronism, resistant hypertension, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: https://doaj.org/toc/1524-6175; https://doaj.org/toc/1751-7176

Access URL: https://doaj.org/article/07018f3809254764940c5bba22d8894f

Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes

Authors: Muhammad Shahzeb Khan, Janice P. Lea

Source: BMC Nephrology, Vol 25, Iss 1, Pp 1-14 (2024)

Subject Terms: Chronic kidney disease, Combination therapy, Finerenone, Sodium-glucose cotransporter-2 inhibitor, Glucagon-like peptide-1 receptor agonist, Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2369

Access URL: https://doaj.org/article/d150c7a24bb44447a794c83bcf72ab52

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison

Authors: David Cherney, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, Neil Hawkins

Source: Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 169-180 (2024)

Subject Terms: chronic kidney disease (CKD), type 2 diabetes (T2D), finerenone, canagliflozin, sodium glucose cotransporter 2 inhibitors (SGLT2i), matching-adjusted indirect comparison (MAIC), Public aspects of medicine, RA1-1270, Business, HF5001-6182

File Description: electronic resource

Relation: https://www.mdpi.com/2001-6689/12/3/14; https://doaj.org/toc/2001-6689

Access URL: https://doaj.org/article/dff937541dc9404db1fe3b6590a96398

Chlorthalidone as Secondary Treatment in HFpEF?

Authors: Gelfman, Daniel M. ^⁎

Source: In The American Journal of Medicine March 2025 138(3):416-418

Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY

Authors: Singh, Ajay K. ^{a, b, ∗}, James, Glen ^c, Anker, Stefan D. ^{d, e}, Pitt, Bertram ^f, Rossing, Peter ^{g, h}, Ruilope, Luis M. ^{i, j, k}, Farjat, Alfredo E. ^l, Farag, Youssef M.K. ^{m, n}, Roberts, Luke ^o, Filippatos, Gerasimos ^p

Source: In JACC: Advances February 2025 4(2)

New strategies for the treatment of hyperkalemia

Authors: Masi, Stefano ^{a, ⁎}, Dalpiaz, Herman ^b, Piludu, Sara ^b, Piani, Federica ^c, Fiorini, Giulia ^c, Borghi, Claudio ^{c, d}

Source: In European Journal of Internal Medicine February 2025 132:18-26

Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial

Authors: Mc Causland, Finnian R. ^{a, ∗}, Vaduganathan, Muthiah ^a, Claggett, Brian L. ^a, Kulac, Ian J. ^a, Desai, Akshay S. ^a, Jhund, Pardeep S. ^b, Henderson, Alasdair D. ^b, Brinker, Meike ^c, Perkins, Robert ^d, Scheerer, Markus F. ^e, Schloemer, Patrick ^f, Lam, Carolyn S.P. ^g, Senni, Michele ^h, Shah, Sanjiv J. ⁱ, Voors, Adriaan A. ^j, Zannad, Faiez ^k, Pitt, Bertram ^l, McMurray, John J.V. ^b, Solomon, Scott D. ^a

Source: In Journal of the American College of Cardiology 21 January 2025 85(2):159-168

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF

Authors: Yang, Mingming ^a, Henderson, Alasdair D. ^a, Talebi, Atefeh ^a, Atherton, John J. ^b, Chiang, Chern-En ^c, Chopra, Vijay ^d, Comin-Colet, Josep ^e, Kosiborod, Mikhail N. ^f, Kerr Saraiva, Jose F. ^g, Claggett, Brian L. ^h, Desai, Akshay S. ^h, Kolkhof, Peter ⁱ, Viswanathan, Prabhakar ⁱ, Lage, Andrea ^j, Lam, Carolyn S.P. ^k, Senni, Michele ^l, Shah, Sanjiv J. ^m, Rohwedder, Katja ⁿ, Voors, Adriaan A. ^o, Zannad, Faiez ^p, Pitt, Bertram ^q, Vaduganathan, Muthiah ^h, Jhund, Pardeep S. ^a, Solomon, Scott D. ^h, McMurray, John J.V. ^{a, ∗}

Source: In Journal of the American College of Cardiology 21 January 2025 85(2):120-136